Whilst we expect that infants who are treated with anti-VEGF will have higher rates and severity of myopia than those with ROP that are not treated, most of the data did not account for birthweight, ethnicity, follow-up, and severity of ROP. Here, VEGFA is linked to retinopathy of prematurity.